Showing results (21-30 of 415) with videos related to
Sort By:
Pageof 42
American Journal of Hematology|July 16, 2011
World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and managementJason GotlibMayo Clinic Proceedings|July 13, 2005
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosisAyalew Tefferi, D Gary GillilandCell Cycle (Georgetown, Tex.)|March 14, 2007
Oncogenes in myeloproliferative disordersAyalew Tefferi, D Gary GillilandCell Cycle (Georgetown, Tex.)|June 23, 2005
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi, D Gary GillilandCell Stem Cell|March 7, 2009
A radical bailout strategy for cancer stem cellsZuzana Tothova, D Gary GillilandCancer Cell|October 7, 2008
Going with the flow: JAK-STAT signaling in JMMLDemetrios Kalaitzidis, D Gary GillilandCell Stem Cell|March 29, 2008
FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic systemZuzana Tothova, D Gary GillilandCurrent Hematologic Malignancy Reports|April 29, 2010
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspectiveMartha Wadleigh, D Gary GillilandCancer Cell|July 18, 2006
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesisJennifer L Rocnik, D Gary GillilandBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2002
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantationD Gary Gilliland, John G GribbenPageof 42